



IFW

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q87992

Andrew N. MARGIORIS, et al.

Appln. No.: 10/535,307

Group Art Unit: 1615

Confirmation No.: 3693

Examiner: Not Yet Assigned

Filed: December 7, 2005

For: USE OF THE CRH (CORTICOTROPIN RELEASING HORMONE) - UCN (UROCORTIN)
SYSTEM IN THE TREATMENT OF INFLAMMATORY DISEASES

REQUEST FOR CORRECTED OFFICIAL FILING RECEIPT

ATTN: Office of Initial Patent Examination
Filing Receipt Correction
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

We enclose a copy of the Official Filing Receipt for the above-identified application and request the following correction:

Assignment For Published Patent Application
BIONATURE E.A. LIMITED

Verification for the requested correction is indicated on the Assignment filed December 7, 2005.

Respectfully submitted,

Brian W. Mannon
Registration No. 32,778

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE


23373

CUSTOMER NUMBER

Date: June 14, 2006



UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/535,307	12/07/2005	1615	615	Q87992	10	14	4

23373
 SUGHRUE MION, PLLC
 2100 PENNSYLVANIA AVENUE, N.W.
 SUITE 800
 WASHINGTON, DC 20037

CONFIRMATION NO. 3693

FILING RECEIPT



OC000000018260568

Date Mailed: 03/13/2006

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Andrew N Margioris, Heraklion, GREECE;
 Achille Gravanis, Herklion, GREECE;

Assignment For Published Patent Application
SIGNATURE E.A. LIMITED

Power of Attorney: The patent practitioners associated with Customer Number 23373.

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/IB03/05429 11/26/2003

Foreign Applications

GREECE 20020100513 11/26/2002

Projected Publication Date: 06/22/2006

Non-Publication Request: No

Early Publication Request: No

** SMALL ENTITY **

Title

Use of the crh (corticotropin releasing hormone)-ucn (urocortin) system in the treatment of

Assignment

Whereas, We, Andrew N. MARGIORIS and Achille GRAVANIS, both of c/o University of Crete, School of Medicine, P.O. Box 2208, GR-71003 HERAKLION, Greece, hereinafter called assignors, have invented certain improvements in

USE OF THE CRH (CORTICOTROPIN RELEASING HORMONE) - UCN (UROCORTIN) SYSTEM IN THE TREATMENT OF INFLAMMATORY DISEASES

and executed an application for Letters Patent of the United States of America therefor on 17 May 2005; and

Whereas, BIONATURE E.A. LIMITED of Poseidon, 2406 EGOMI, NICOSIA, CYPRUS (assignee), desires to acquire the entire right, title, and interest in the application and invention, and to any United States patents to be obtained therefor;

Now therefore, for valuable consideration, receipt whereof is hereby acknowledged,

I/We, the above named assignor(s), hereby sell, assign and transfer to the above named assignee, its successors and assigns, the entire right, title and interest in the application and the invention disclosed therein for the United States of America, including the right to claim priority under 35 U.S.C. §119, and I/we request the Director of the U.S. Patent and Trademark Office to issue any Letters Patent granted upon the invention set forth in the application to the assignee, its successors and assigns; and I/we will execute without further consideration all papers deemed necessary by the assignee in connection with the United States application when called upon to do so by the assignee.

I/We hereby authorize and request our attorneys SUGHRUE MION, PLLC of 2100 Pennsylvania Avenue, NW, Washington, DC 20037-3213 to insert here in parentheses (Application number _____ and Confirmation number Not Yet Known, filed _____) the application number and filing date of said application when known.

Date: June 24, 2005


S/Andrew N. MARGIORIS

Date: June 27, 2005


S/Achille GRAVANIS